VERONA PHARMA
VRNADrugs in Pipeline
14
Phase 3 Programs
2
Upcoming Catalysts
3
Next Catalyst
Aug 5, 2026
12wMarket Overview
Stock performance and key metrics
3 upcoming, 2 past
Ensifentrine 3 mg twice daily
COPD
Ensifentrine
Chronic Obstructive Pulmonary Disease
Nebulized Ensifentrine Suspension; 3 mg
Non-cystic Fibrosis Bronchiectasis
Part A: RPL554
Pulmonary Disease, Chronic Obstructive
Glycopyrrolate (85 μg)
Chronic Obstructive Pulmonary Disease
Tiotropium/olodaterol (Respimat)
COPD
Ensifentrine 3 mg
Chronic Obstructive Pulmonary Disease
RPL554
Cystic Fibrosis
Salbutamol
Chronic Obstructive Pulmonary Disease
Glycopyrrolate 21.25 mcg
Chronic Obstructive Pulmonary Disease
1.5 mg RPL554 plus tiotropium
Chronic Obstructive Pulmonary Disease Moderate
Ensifentrine Dose 1
Coronavirus Infection
Part B: RPL554
COPD
RPL554 suspension
COPD
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Ensifentrine 3 mg twice daily | Phase 3 | COPD | - | - |
Ensifentrine | Phase 3 | Chronic Obstructive Pulmonary Disease | - | - |
Nebulized Ensifentrine Suspension; 3 mg | Phase 2 | Non-cystic Fibrosis Bronchiectasis | - | - |
Part A: RPL554 | Phase 2 | Pulmonary Disease, Chronic Obstructive | - | - |
Glycopyrrolate (85 μg) | Phase 2 | Chronic Obstructive Pulmonary Disease | - | - |
Tiotropium/olodaterol (Respimat) | Phase 2 | COPD | - | - |
Ensifentrine 3 mg | Phase 2 | Chronic Obstructive Pulmonary Disease | - | - |
RPL554 | Phase 2 | Cystic Fibrosis | - | - |
Salbutamol | Phase 2 | Chronic Obstructive Pulmonary Disease | - | - |
Glycopyrrolate 21.25 mcg | Phase 2 | Chronic Obstructive Pulmonary Disease | - | - |
1.5 mg RPL554 plus tiotropium | Phase 2 | Chronic Obstructive Pulmonary Disease Moderate | - | - |
Ensifentrine Dose 1 | Phase 2 | Coronavirus Infection | - | - |
Part B: RPL554 | Phase 2 | COPD | - | - |
RPL554 suspension | Phase 2 | COPD | - | - |